Back to top
more

AstraZeneca (AZN)

(Delayed Data from NSDQ)

$76.62 USD

76.62
3,915,515

-1.92 (-2.44%)

Updated May 28, 2024 04:00 PM ET

After-Market: $76.61 -0.01 (-0.01%) 5:42 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 39% (152 out of 250)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

AstraZeneca's (AZN) Imfinzi Early-Stage Lung Cancer Study Fails

by Zacks Equity Research

AstraZeneca's (AZN) PACIFIC-2 study on Imfinzi fails to achieve statistical significance for the primary endpoint of progression-free survival.

Ionis (IONS) Early-Stage Genetic Disorder Data Shows Promise

by Zacks Equity Research

Preliminary data from a phase I/IIa study on Ionis' (IONS) pipeline candidate, ION582, shows encouraging EEG and clinical observations in a phase I/IIa study.

Here is What to Know Beyond Why AstraZeneca PLC (AZN) is a Trending Stock

by Zacks Equity Research

Recently, Zacks.com users have been paying close attention to Astrazeneca (AZN). This makes it worthwhile to examine what the stock has in store.

Ironwood's (IRWD) Q3 Earnings Miss Mark, Linzess Volume Rises

by Zacks Equity Research

Ironwood's (IRWD) third-quarter 2023 earnings miss estimates, while revenues beat the same. Linzess collaboration revenues drive the top line.

AstraZeneca (AZN) Buys Global Rights to Oral Obesity Candidate

by Zacks Equity Research

To cash in on the rising demand for obesity drugs, AstraZeneca (AZN) in-licenses exclusive rights to ECC5004, a novel oral GLP-1RA therapy, from private Chinese biotech Eccogene.

AstraZeneca (AZN) Beats on Q3 Earnings & Sales, Ups 2023 View

by Zacks Equity Research

AstraZeneca (AZN) beats third-quarter estimates for earnings and sales. The company raises its sales and EPS guidance for 2023.

Jobless Claims Decreased More Than Expected

by Zacks Equity Research

Jobless Claims Decreased More Than Expected

Mark Vickery headshot

Pre-Markets Strong on Higher Bond Rates, Mixed Earnings

by Mark Vickery

While this positive sentiment is welcome, we note bond yield rates going higher this morning.

Astrazeneca (AZN) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates

by Zacks Equity Research

The headline numbers for Astrazeneca (AZN) give insight into how the company performed in the quarter ended September 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

AstraZeneca (AZN) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

Higher sales of AstraZeneca's (AZN) key medicines, Lynparza, Tagrisso, Imfinzi and Farxiga, are likely to have driven sales in the third quarter, partially offset by lower sales of legacy drugs.

Unlocking Q3 Potential of Astrazeneca (AZN): Exploring Wall Street Estimates for Key Metrics

by Zacks Equity Research

Besides Wall Street's top -and-bottom-line estimates for Astrazeneca (AZN), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended September 2023.

Ionis (IONS) Q3 Loss Wider Than Expected, Sales Beat Estimates

by Zacks Equity Research

Ionis (IONS) incurs a wider-than-expected third-quarter loss. Sales beat estimates. The company re-affirms its previously issued financial guidance for 2023.

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

by Zacks Equity Research

Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.

Astrazeneca (AZN) Rises But Trails Market: What Investors Should Know

by Zacks Equity Research

In the most recent trading session, Astrazeneca (AZN) closed at $63.23, indicating a +0.46% shift from the previous trading day.

Can High Benefits and Expenses Affect Cigna (CI) Q3 Earnings?

by Zacks Equity Research

Cigna's (CI) third-quarter results are likely to reflect growth in medical customers and pharmacy revenues.

Amgen (AMGN) Beats on Q3 Earnings Beat, Lags Sales, Ups View

by Zacks Equity Research

Amgen (AMGN) beats Q3 estimates for earnings but misses on sales. Following the acquisition of Horizon Therapeutics, it raises earnings and sales guidance for 2023.

Is Trending Stock AstraZeneca PLC (AZN) a Buy Now?

by Zacks Equity Research

Astrazeneca (AZN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Will Lower CenterWell Profit Hurt Humana's (HUM) Q3 Earnings?

by Zacks Equity Research

Humana's (HUM) third-quarter results are likely to reflect higher investment income and premiums.

Sanofi (SNY) Beats on Q3 Earnings, to Spin-Off Consumer Unit

by Zacks Equity Research

Sanofi (SNY) beats third-quarter estimates for earnings but misses the same for sales. It announces plans to separate its Consumer unit into a new public listed company.

Merck (MRK) Q3 Earnings Top Estimates, COVID Drug Boosts Sales

by Zacks Equity Research

Merck (MRK) beats Q3 estimates for earnings and sales. It raises its 2023 guidance. Stock rises in pre-market.

Eli Lilly (LLY) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

On Eli Lilly's (LLY) third-quarter conference call, investor focus is likely to be on the sales of its new diabetes drug, Mounjaro.

Astrazeneca (AZN) Stock Moves -0.56%: What You Should Know

by Zacks Equity Research

Astrazeneca (AZN) closed at $64.21 in the latest trading session, marking a -0.56% move from the prior day.

Moderna (MRNA) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

Investors' focus will likely be on updates on Moderna's (MRNA) pipeline, especially its late-stage pipeline candidates, when it reports third-quarter earnings.

Amgen (AMGN) to Report Q3 Earnings: Will It Beat Estimates?

by Zacks Equity Research

Volume growth from Amgen's (AMGN) key drugs like Prolia, Repatha and Evenity, among others, is expected to have been partially offset by biosimilar/generic competition for mature drugs.

Pfizer (PFE) to Report Q3 Earnings: Here's What to Expect

by Zacks Equity Research

Pfizer (PFE) expects better non-COVID operational revenue growth sequentially in the third quarter, driven by its key products, new launches as well as newly acquired products.